Alterity presents positive ATH434 phase II data at key Parkinson’s conference

Alterity Therapeutics (ASX:ATH) CEO Dr David Stamler presented new analyses from the phase II double-blinded ATH434-201 trial in MSA, showing positive effects on slowing disease progression and ...

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...
TipRanks on MSN

Alterity Therapeutics presents data from ATH434 Phase 2 trial

Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy ...
TMCnet

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

“We look forward to presenting data from the Phase 2 double-blind clinical trial of ATH434 at MDS 2025 and educating leaders in the movement disorder community on its potential as a first-ever ...

Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at ...
Medical Xpress

Multiple sclerosis does not worsen menopause symptoms, study finds

The largest study of its kind has found menopause is not associated with an increased risk of disability in women with multiple sclerosis (MS). Until now, the impact of reduced sex hormones on women ...
IEEE

A Space Aware Temporal Convolutional Neural Networks Approach for Enhanced Diagnosis of Multiple Sclerosis Brain Atrophy using MR images

Abstract: The autoimmune condition known as multiple sclerosis (MS) leads to inflammation and demyelination, resulting in a gradual deterioration of the central nervous system. A significant sign of ...

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg dosesMELBOURNE, Australia and SAN FRANCISCO, Sept. 15, 2025 (GLOBE ...
Frontiers

Case Report: When multiple system atrophy masquerades as CASPR2 autoimmune encephalopathy: a diagnostic pitfall

1 Clinical Research Center, Xuanwu Hospital Capital Medical University, Beijing, China 2 Department of Neurology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, ...
Seeking Alpha

Teva gets FDA fast track status for multiple system atrophy drug

Teva Pharmaceuticals (NYSE:TEVA) said that the U.S. FDA has granted fast track designation to its experimental therapy TEV-56286 (emrusolmin) for treating Multiple System Atrophy. Emrusolmin, ...
Business Insider

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New ...